Walvax’s 23-valent pneumococcal vaccine enters the Latin American market for the first time
August 26, 2025
Source: drugdu
123
According to a report from Southern Finance on August 26, Walvax BioAccording to news, recently, the 23-valent pneumococcal polysaccharide vaccine (hereinafter referred to as "23-valent pneumococcal vaccine") produced by Yuxi Watson Biotechnology Co., Ltd. , a subsidiary of Walvax Biotechnology Holdings, completed its first export delivery to El Salvador, marking the first time that Walvax Biotechnology has exported 23-valent pneumococcal polysaccharide vaccine to El Salvador.The product has officially launched in the Latin American market. As the world's first preservative-free 23-valent pneumococcal polysaccharide vaccine, it is suitable for children over 2 years old and high-risk adults. Global sales have exceeded 14 million doses.
https://finance.eastmoney.com/a/202508263494831241.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Multiple batches of quadrivalent influenza virus split vaccine have been sub-packaged and submitted for lot release approval; expected to be released to the market soon after approval December 12, 2025
- Ab&B Bio-Tech CO., LTD. JS Lyophilized Human Rabies Vaccine Initiates Phase III Clinical Trials December 12, 2025
- The ‘Sweetest’ HPV Vaccine Market is Gone | Haibin Interview December 12, 2025
- InnoCare Pharma announced that its first independently developed next-generation TRK inhibitor, zoletrazinib, has been approved for marketing in China December 12, 2025
- Is PD-1/VEGF dual antibody + ADC becoming the standard configuration? December 12, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
